Cryopreservation protective agent, preparation method and application thereof and skin cryopreservation method
Through the frozen protection agent of betaine and trehalose, the formation and growth of ice crystals are inhibited, and the existing frozen protection agents are solved, and the problems of high toxicity, difficulty in eluting and poor biocompatibility are achieved, so that the deep and low temperature of the skin is achieved Freeze protection, maintaining the structural and biomechanical properties of the skin.
Patent Information
- Application Number
- CN202410970452.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
AI Technical Summary
The existing frozen storage protective agents are highly toxic, difficult to elute, and have poor biocompatibility, resulting in the problems of stress accumulation and ice crystal damage during the freezing of the organ.
The mixture of betaine and trehalose is used as a frozen protection agent. Through the electrostatic interaction of betaine and the polyhydroxy structure of trehalose, the formation and growth of ice crystals are inhibited, and the recrystallization of ice crystals is regulated to form a good biocompatible freezing protective agent.
Effectively inhibit the formation and growth of ice crystals, reduce mechanical damage and stress accumulation during the freezing process of skin, maintain the structural integrity and biomechanical properties of the skin, and prolong the cryopreservation time of the skin.
Smart Images

Figure CN118923664A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of cryopreservation agents, and specifically relates to a cryoprotectant, a preparation method and application thereof, and a skin cryopreservation method. Background Art
[0002] Skin is the largest organ in the human body. It provides mechanical support and is an important protective barrier against environmental factors. However, the integrity of this barrier is often damaged in various forms, such as thermal burns, traumatic injuries, and pressure ulcers. Approximately 486,000 patients are treated for skin burns in the United States each year, at a cost of nearly $2 billion. Skin transplantation plays a key role in regenerative medicine, providing an important solution for severe skin injuries and is also a leading intervention for complex organ transplantation. Autologous split-thickness skin transplantation is considered the gold standard treatment for large-area burns and full-thickness skin injuries. However, due to the scarcity of patient skin and the increased likelihood of secondary injury, allogeneic skin transplantation has gradually become the preferred treatment option. However, scarce donor skin has become a huge obstacle to its clinical application. Many skin grafts are discarded because they cannot be preserved for a long time, resulting in reduced viability of the graft. Ex vivo skin grafts may lose up to 50% of their viability within the first 24 hours. Therefore, there is an urgent need to develop reliable and effective ex vivo skin preservation strategies to mitigate graft damage.
[0003] Cryopreservation is the most effective technology for long-term preservation of tissues and organs. Many countries, including Italy, Israel, India and Japan, have established skin banks through cryopreservation technology. This allows donor skin grafts to be stored in ultra-low temperature freezers at -80°C or liquid nitrogen containers for optimal long-term storage conditions. However, the freezing and thawing process can lead to the formation and growth of ice crystals, which pose a major threat to the structural integrity and biomechanical properties of the skin. After transplantation, cryopreserved skin is impaired in sensory nerve regeneration, exhibits uneven pigmentation and lacks hair follicle regeneration. How to effectively preserve the original physiological function and structural integrity of the skin remains a challenge.
[0004] Currently, 15wt% glycerol (Gly) and 15wt% dimethyl sulfoxide (DMSO) are commonly used as cryoprotectants for skin and cell cryopreservation. However, when used at a concentration exceeding 2wt%, DMSO can cause cell damage and even genetic changes. In addition, the limited elution capacity of Gly limits its application in the field of skin preservation. Therefore, it is of great significance to study strategies to replace traditional small molecule cryoprotectants. Summary of the invention
[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a cryoprotectant and a preparation method and application thereof, as well as a method for freezing skin.
[0006] To achieve the above object, the technical solution adopted by the present invention is:
[0007] A cryoprotectant comprises an antifreeze agent and a balancing solution; the antifreeze agent is a mixture of betaine and trehalose.
[0008] The mass proportion of the betaine in the cryoprotectant is 8-12%, preferably 10%; the mass proportion of the trehalose in the cryoprotectant is 3-7%, preferably 5%.
[0009] The balancing solution is one of PBS buffer, DPBS buffer or physiological saline.
[0010] The present invention also includes a method for preparing the cryoprotectant, comprising the following steps: adding an antifreeze agent to a balancing solution to prepare a cryoprotectant of a certain concentration; preferably, the mass concentration of the antifreeze agent is 10-20%, preferably 15%.
[0011] The present invention also includes an application of the cryoprotectant for cryopreservation of tissues or organs. Preferably, the organ is skin.
[0012] The present invention also includes a method for freezing skin, comprising the following steps:
[0013] (1) Pre-cool the cryoprotectant in a refrigerator;
[0014] (2) placing the ex vivo skin in a cryopreservation bag, adding an appropriate amount of the cryoprotectant prepared in step (1), and placing it in a refrigerator for equilibrium, preferably for 1-3 hours; more preferably for 2 hours; until the osmotic pressure is balanced to allow uniform mass transfer;
[0015] (3) Place the cryopreservation bag in a programmable temperature controller, equilibrate at 4°C, cool to -80°C at a rate of 0.5-5°C / min, equilibrate, and then transfer to liquid nitrogen for freezing;
[0016] (4) Rewarm the tube until the ice crystals melt, then remove the tube immediately and rinse the cryoprotectant with saline.
[0017] Preferably, the rewarming method in step (4) is to immerse the cryopreservation bag in a 37° C. water bath and shake it continuously.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] Controlling and inhibiting ice formation is a key aspect in reducing damage during skin cryopreservation. The role of antifreeze in inhibiting ice crystal growth is mainly based on its antifreeze molecular structure and chemical properties. Betaine has a unique structural characteristic of being electrically neutral with opposite charges at both ends of its molecule, which enables it to form a strong binding energy with water molecules through electrostatic interaction, inhibiting the regular arrangement of water molecules for freezing, thereby inhibiting ice nucleation; and trehalose, due to its surrounding polyhydroxy structure, can effectively bind to ice, preventing water molecules from diffusing to the ice crystal interface, thereby inhibiting the growth of ice crystals.
[0020] Based on this, the addition of betaine and trehalose in the present invention regulates the formation and growth of ice crystals to reduce the mechanical damage caused by ice crystals during skin cryopreservation, the stress surge and stress accumulation caused by phase change, preserves the structural integrity and biomechanical system of the skin, and further improves the cryopreservation efficiency of skin transplants.
[0021] 1) The present invention avoids the use of traditional cryoprotectants with high toxicity and difficulty in elution, and develops a cryoprotectant with excellent biocompatibility, effective ice inhibition performance, reduced cryopreservation thermal stress accumulation and maintained good fiber structure, for deep cryopreservation of skin. Its basic components are betaine, trehalose and balance solution. Among them, betaine is a small molecule with good biocompatibility and permeability. It has excellent osmotic pressure regulation ability and has obvious advantages in improving the mass transfer effect of the protectant; in addition, because its two ends of the molecule carry opposite charges and the overall electrical neutrality, it has a strong binding ability with water molecules and has the ability to regulate ice crystals. It can effectively inhibit the formation of ice nuclei, so that ice nuclei preferentially form ice in the protectant rather than at the interface between the skin and the protectant, avoiding ice crystals from damaging skin fibers. Trehalose is a non-permeable cryoprotectant. Due to its polyhydroxy structure, it can form strong hydrogen bonds with the phospholipid bilayer, thereby stabilizing the biological macromolecular structures such as cell membranes and proteins, and protecting the structural integrity of the cytoplasmic matrix.
[0022] 2) The present invention measures the ice nucleation, ice growth and ice crystal recrystallization ability of the cryoprotectant, compares the ice inhibition effect of traditional small molecule cryoprotectants, and comprehensively optimizes the cryoprotectant formula. Specifically, the mass concentration of betaine was investigated from 8% to 12%, and the mass concentration of trehalose was investigated from 3% to 7%. It was found that when the concentration of betaine was 8% and the concentration of trehalose was 7%, the non-frozen water content formed by the system was less, and the non-frozen water content gradually increased with the increase of betaine concentration and the decrease of trehalose concentration, indicating that the protective agent combined with water to inhibit ice formation; when the concentration of betaine was 10% and the concentration of trehalose was 5%, the inhibitory effect on ice crystal growth was the greatest; as the proportion of betaine in the cryoprotectant increased, the inhibitory effect on ice crystal recrystallization increased; and compared with the same concentration of Gly and DMSO, the ice inhibition effect of the protective agent was higher than them. Taking all factors into consideration, the optimal mass concentrations of betaine and trehalose are 10% and 5%, respectively.
[0023] 3) The present invention utilizes the above-mentioned cryoprotectant to freeze the skin in liquid nitrogen for six months. The results show that the skin still exhibits complete tissue structure, good vitality and biomechanical properties, and its effect is better than that of using the traditional cryoprotectant Gly and DMSO for freezing for one month.
[0024] In summary, in order to solve the problems of high toxicity, difficulty in elution, poor biocompatibility of existing cryoprotectants, and stress accumulation and ice crystal damage during organ cryopreservation, the present invention has developed a cryoprotectant formula with good biocompatibility and effective inhibition of ice nucleus formation and growth based on zwitterionic betaine and trehalose with good biocompatibility. The present invention explores the ability of the cryoprotectant to regulate ice crystals for the first time and successfully applies it to deep-low temperature cryopreservation of skin. Among them, betaine has opposite charges at both ends of its molecule and is electrically neutral as a whole, so that it mainly forms a strong binding ability with water molecules through electrostatic interaction, inhibiting the regular arrangement of water molecules. It can effectively inhibit the formation of ice nuclei and has the ability to regulate ice crystals, so that ice nuclei preferentially form ice in the protectant rather than at the interface between the skin and the protectant, avoiding ice crystals from damaging skin fibers; in addition, trehalose, due to its polyhydroxy structure, can form strong hydrogen bonds with the phospholipid bilayer, thereby stabilizing the biological macromolecular structures such as cell membranes and proteins, and protecting the integrity of the cytoplasmic matrix structure. The present invention is the first to develop a deep-temperature cryoprotectant for skin cryopreservation by regulating the ice-controlling ability of betaine and trehalose, thereby making it possible to achieve long-term and efficient preservation of ex vivo skin. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 It is a schematic diagram of a method for cryopreservation of skin using a cryoprotectant of the present invention;
[0026] Figure 2This is a graph showing the ice nucleation ability and non-frozen water content of different protective agents in Example 1 of the present invention;
[0027] Figure 3 This is a graph showing the ice crystal growth ability results of different protective agents in Example 1 of the present invention;
[0028] Figure 4 This is a graph showing the ice crystal recrystallization ability results of different protective agents in Example 1 of the present invention;
[0029] Figure 5 This is a graph showing the protective agent mass transfer test results in Example 2 of the present invention;
[0030] Figure 6 This is a test result diagram of different cooling rates in Example 2 of the present invention;
[0031] Figure 7 This is a diagram showing the histomorphological results of the skin after deep cryopreservation in Example 2 of the present invention;
[0032] Figure 8 This is a graph showing the collagen fiber content of skin after deep cryopreservation in Example 2 of the present invention;
[0033] Fig. 9 This is a graph showing the biomechanical properties of skin after deep cryopreservation in Example 2 of the present invention;
[0034] Fig.10 This is a graph showing the cell activity results of the skin after deep cryopreservation in Example 2 of the present invention. DETAILED DESCRIPTION
[0035] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention is further described in detail below in conjunction with the accompanying drawings and the best embodiments.
[0036] Example 1
[0037] Preparation of cryoprotectant: betaine and trehalose were dissolved in PBS buffer respectively to prepare three mixed solutions of betaine and trehalose with a total mass concentration of 15%;
[0038] They are: 8g betaine and 7g trehalose dissolved in 85g PBS buffer solution;
[0039] 10 g betaine and 5 g trehalose were dissolved in 85 g PBS buffer solution;
[0040] 12 g of betaine and 3 g of trehalose were dissolved in 85 g of PBS buffer solution, stirred thoroughly and set aside as cryoprotectants A, B, and C.
[0041] Preparation of traditional cryoprotectant as a comparative example: 15 g DMSO and 15 g betaine were dissolved in 85 g PBS buffer solution, stirred thoroughly and set aside as D and E.
[0042] Ability of cryoprotectants to regulate ice crystals:
[0043] (1) Ice nucleation suppression capability test: Figure 1 As shown, the cryoprotectant is cooled using a cold stage, and the freezing condition is observed using a microscope. 1uL of cryoprotectant is placed on the sample stage to be tested, and the temperature is cooled at a rate of 5°C / min. During the cooling process, when the sample droplet to be tested changes from transparent to opaque within 1s, the temperature at this time is recorded as the ice nucleation temperature.
[0044] (2) Freezing point depression ability and non-frozen water content detection: The above-mentioned cryoprotectants were analyzed using a differential scanning calorimeter (DSC). Weigh 10 mg of cryoprotectant and cool it from 20°C to -40°C at a cooling rate of 10°C / min using DSC, and then heat it to 20°C at a heating rate of 2°C / min. The non-frozen water content can be obtained by integrating the endothermic peaks in the heating period. The results are as follows: Figure 2 The test results of freezing point depression ability and non-frozen water content of different cryoprotectants are shown. In the figure, Betaine is pure betaine with a concentration of 15%; Tre is pure trehalose with a concentration of 15%, BT-1 is sample A, BT-2 is sample B, Bt-3 is sample C, Gly is pure glycerol with a concentration of 15%, and pure DMSO with a concentration of 15%; the results show that the ice nucleation ability of the cryoprotectant group with different concentrations is much lower than that of the water group, and is significantly lower than that of the traditional protectant group (Gly and DMSO), indicating its excellent ability to inhibit ice nucleation; when the concentration of betaine is 8% and the concentration of trehalose is 7% (BT-1), the non-frozen water content formed by the system is relatively small, and the non-frozen water content gradually increases with the increase of betaine concentration and the decrease of trehalose concentration, indicating that the protectant forms a strong bond with water molecules, inhibiting the regular arrangement of water molecules and thus inhibiting ice formation.
[0045] (3) Ice crystal growth ability test: The above cryoprotectants were tested for ice crystal growth rate using a nanoliter osmometer. A small amount of cryoprotectant and sample well were taken, and the temperature was lowered to -25°C using a nanoliter osmometer to completely freeze them. The temperature was gradually raised until only one ice crystal remained and could remain unchanged for 20 seconds. The temperature was then lowered to a supercooling degree of 0.04°C (ΔT = 0.04) to evaluate the growth rate of the ice crystal. The results are as follows: Figure 3The test results show that different cryoprotectants have a greater ability to inhibit ice crystal growth. Even when combined with trehalose solution, it can still maintain a good ability to inhibit ice crystal growth. When the concentration of betaine is 10% and the concentration of trehalose is 5% (BT-2), the inhibitory effect on ice crystal growth is the greatest.
[0046] (4) Ice crystal recrystallization ability test: The above cryoprotectants were analyzed using the cold stage freezing method. 12uL of cryoprotectant was quickly dripped onto the crucible from a height of 1.5m, and then placed on a -60℃ cold stage. The temperature was then raised to -6℃ at a rate of 20℃ / min, and the ice crystal size was evaluated after 30 minutes of freezing. The results are as follows: Figure 4 The test results of different cryoprotectants on the ability of ice crystal recrystallization are shown. The results show that as the proportion of betaine in the cryoprotectant increases, the inhibitory effect on ice crystal recrystallization is enhanced; and compared with the same concentration of Gly and DMSO, the inhibitory effect of this protectant on ice crystal recrystallization is higher than them.
[0047] In summary, the ice crystal regulation ability of the cryoprotectant was evaluated. As the concentration of betaine increased, the non-frozen water content in the system increased, the ice crystal growth rate decreased, and the ability to inhibit ice crystal recrystallization increased. When the betaine concentration reached 10%, the ice crystal growth rate of the system was low, and further increasing the betaine concentration did not significantly increase the ability to inhibit ice crystal recrystallization in the system. Therefore, the cryoprotectant BT-2 was selected for subsequent experiments.
[0048] Example 2: Cryopreservation experiment of skin
[0049] Skin cryopreservation method: 1) Place the ex vivo skin in a 50 mL cryopreservation bag containing 30 mL of the cryoprotectant B, remove air bubbles and heat seal, place in a 4°C refrigerator for 1 minute to 3 hours to achieve the mass transfer equilibrium of the protectant, measure the osmotic equilibrium time of the protectant by a freezing point osmotic pressure tester, and finally select the equilibrium time as 2 hours ( Figure 5 );
[0050] The cryopreservation bag containing the skin was transferred to a programmable temperature controller for gradient cooling. After equilibration at 4°C for 2 minutes, the temperature was cooled from 4°C to -80°C at a rate of 0.5°C / min, 1°C / min, and 5°C / min, respectively. The skin was then quickly transferred to a liquid nitrogen tank and stored for 1 month and 6 months, respectively. Figure 1 ).
[0051] The biomechanical properties of the skin were evaluated using a universal testing machine, and the skin was cut using a dumbbell-shaped cutter (narrow parallel portion length: 16 mm; narrow parallel portion width: 4 mm; total length: 57 mm; total width: 8.5 mm). The gauge length was set to 1 cm, and the skin was fixed with the instrument's clamps before a uniaxial tensile test was performed at a rate of 10 mm / min until the skin broke. The tensile stress-strain curve was analyzed to obtain the breaking strength and breaking elongation, and the slope of the linear region of the curve was calculated to obtain the Young's modulus. The results are shown in Figure 1. Figure 6 Shown, Figure 6 V0.5, V1, and V5 correspond to the cooling rates of 0.5℃ / min, 1℃ / min, and 5℃ / min, respectively; from the results, it can be seen that when the cooling rate is 1℃ / min, the elongation at break and Young's modulus of the skin are closer to those of fresh skin, and the final cooling rate is 1℃ / min.
[0052] Comparative Example 1
[0053] Traditional method for cryopreservation of skin: place the ex vivo skin in a cryobag containing 30 mL 15% DMSO (15 g DMSO dissolved in 85 g PBS buffer) and incubate for 2 hours; transfer the cryobag containing the skin to a programmable temperature controller for gradient cooling, equilibrate at 4°C for 2 minutes, then cool from 4°C to -80°C at a rate of 1°C / min, and then quickly transfer to a liquid nitrogen tank for storage for 1 month.
[0054] Comparative Example 2
[0055] Traditional method for cryopreservation of skin: ex vivo skin is placed in a cryobag containing 30 mL 15% Gly (15 g Gly dissolved in 85 g PBS buffer) and incubated for 2 hours; the cryobag containing the skin is transferred to a programmable temperature controller for gradient cooling, and after equilibration at 4°C for 2 minutes, the temperature is lowered from 4°C to -80°C at a rate of 1°C / min, and then quickly transferred to a liquid nitrogen tank for storage for 1 month.
[0056] Steps for rewarming the skin:
[0057] The cryopreservation bag containing the skin was taken out from the liquid nitrogen tank and immersed in a 37°C water bath to rewarm until the ice was completely melted. During this period, the cryopreservation bag was shaken continuously to accelerate the rewarming. After the skin was taken out, it was rinsed several times with cleaning solution and then transferred to physiological saline for use. The traditional method of preserving and rewarming the skin is the same as above.
[0058] The cleaning solution is 0.9% saline solution.
[0059] Detection and analysis of skin cryopreservation protection results.
[0060] 1. Perform the following functional tests on the skin after freezing for 1 month and 6 months and then thawing
[0061] (1) Histomorphological examination: The skin obtained in Example 2 was placed in a 1.5 mL centrifuge tube and fixed with paraformaldehyde for 24 hours, dehydrated with 40% sucrose for 12 hours until the skin precipitated to the bottom of the centrifuge tube, embedded with OCT for 48-64 hours, and then cut into 6 μm thick slices using a freezing microtome. The skin sections were stained according to the instructions of the hematoxylin and eosin (H&E) staining and picrosirius red staining kit to evaluate the tissue density and tissue morphology after cryopreservation.
[0062] (2) Detection of collagen fiber content: The collagen fiber content of frozen skin was analyzed using a hydroxyproline (HYP) kit. An appropriate amount of skin was weighed and cut into pieces, digested with hydrochloric acid at 100°C for 3 h, and then the hydroxyproline content was determined according to the kit instructions.
[0063] (3) Biomechanical properties testing: A universal testing machine was used to evaluate the biomechanical properties of the skin. The skin was cut using a dumbbell-shaped cutter (narrow parallel portion length: 16 mm; narrow parallel portion width: 4 mm; total length: 57 mm; total width: 8.5 mm). The gauge length was set to 1 cm and the skin was fixed with the instrument's clamps before a uniaxial tensile test was performed at a rate of 10 mm / min until the skin broke. The breaking strength and breaking elongation can be obtained by analyzing the tensile stress-strain curve, and the Young's modulus can be obtained by calculating the slope of the linear region of the curve.
[0064] (4) Cell activity detection: Skin cells, mainly fibroblasts, were isolated from skin tissue using collagenase digestion. Specifically, the skin was minced into 2 mm fragments, soaked in 1% penicillin-streptomycin solution for 15 min, and then digested with 0.25% trypsin inhibitor for 30 min and 0.25% type I collagenase for 2 h. The cell suspension was obtained by centrifugation and then cultured at 37°C and 5% CO2 for further testing. 1 mL of 1×10 5 / mL cells and assess cell viability using the Live / Dead kit as directed.
[0065] 2. Results Analysis
[0066] (1) Figure 7 The results of H&E staining and Picrosirius Red staining after cryopreservation of skin are shown. After 1 month and 6 months of cryopreservation, the skin of the cryoprotectant group maintained dense tissue and relatively uniform cell nuclear morphology. Even if the cryopreservation time was extended to 6 months, the structural integrity was still maintained at 98.7%, and the distribution and content of collagen fibers were comparable to those of the fresh group ( Figure 8); Even after 1 month of cryopreservation, the cell nuclear morphology of the Gly group and the DMSO group was uneven, the tissue was loose, and the collagen fiber content was reduced.
[0067] (2) Fig. 9 The results of mechanical properties of skin after cryopreservation are shown. After 1 month and 6 months of cryopreservation, the maximum tensile stress and elongation at fracture of the cryoprotectant group were not significantly different from those of fresh skin; after one month of cryopreservation, the breaking strength and elongation at fracture of the skin in the PBS group, Gly group, and DMSO group were significantly reduced, the Young's modulus in the PBS group was significantly reduced, and the Young's modulus in the Gly group and DMSO group was not significantly different from that in the fresh group.
[0068] (3) Fig.10 The cell viability after cryopreservation of the skin is shown. The survival rates of the cells in the cryoprotectant group were 81.8% and 80.3% after 1 month and 6 months of cryopreservation, respectively; the survival ability of the cells in the Gly group and DMSO group decreased significantly after only 1 month of cryopreservation, and almost no cells survived in the PBS group.
[0069] The above results show that the cryoprotectant based on betaine and trehalose as the main components can protect the skin from osmotic pressure damage and ice crystal damage by regulating ice nucleation and ice crystal growth, maintain the integrity of the skin structure, collagen fiber structure and content, and biomechanical properties, while retaining high cell activity. Therefore, the cryoprotectant and cryopreservation method proposed in the present invention show excellent cryopreservation effect.
[0070] In summary, in order to solve the problems of high toxicity, difficulty in elution, poor biocompatibility of existing cryoprotectants, and stress accumulation and ice crystal damage during organ cryopreservation, the present invention has developed a cryoprotectant formula with good biocompatibility and effective inhibition of ice nucleus formation and growth based on zwitterionic betaine and trehalose with good biocompatibility. The present invention explores the ability of the cryoprotectant to regulate ice crystals for the first time and successfully applies it to deep-low temperature cryopreservation of skin. Among them, betaine has opposite charges at both ends of its molecule and is electrically neutral as a whole, so that it mainly forms a strong binding ability with water molecules through electrostatic interaction, inhibiting the regular arrangement of water molecules. It can effectively inhibit the formation of ice nuclei and has the ability to regulate ice crystals, so that ice nuclei preferentially form ice in the protectant rather than at the interface between the skin and the protectant, avoiding ice crystals from damaging skin fibers; in addition, trehalose, due to its polyhydroxy structure, can form strong hydrogen bonds with the phospholipid bilayer, thereby stabilizing the biological macromolecular structures such as cell membranes and proteins, and protecting the integrity of the cytoplasmic matrix structure. This invention is the first to develop a cryoprotectant for skin cryopreservation by regulating the ice-controlling ability of betaine and trehalose, which makes it possible to achieve long-term and efficient preservation of ex vivo skin structure and function. It not only improves the supply chain of skin cryopreservation, but also provides a promising solution for long-term cryopreservation of organs.
[0071] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A cryoprotectant, characterized in that: It comprises an antifreeze agent and a balancing solution; the antifreeze agent is a mixture of betaine and trehalose.
2. The cryoprotectant according to claim 1, characterized in that The mass proportion of the betaine in the cryoprotectant is 8-12%, preferably 10%; the mass proportion of the trehalose in the cryoprotectant is 3-7%, preferably 5%.
3. The cryoprotectant according to claim 1, characterized in that The balancing solution is one of PBS buffer, DPBS buffer or physiological saline.
4. A method for preparing the cryoprotectant according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: adding an antifreeze agent into a balance solution to prepare a cryoprotectant of a certain concentration; preferably, the mass concentration of the antifreeze agent is 10-20%, preferably 15%.
5. A use of the cryoprotectant according to any one of claims 1 to 3, characterized in that: Applicable to cryopreservation of tissues or organs, preferably, the organ is skin.
6. A method for freezing skin, characterized in that: The steps include: (1) Pre-cool the cryoprotectant in a refrigerator; (2) placing the ex vivo skin in a cryopreservation bag, adding an appropriate amount of the cryoprotectant prepared in step (1), and placing it in a refrigerator for equilibrium, preferably for 1-3 hours; more preferably for 2 hours; until the osmotic pressure is balanced to allow uniform mass transfer; (3) Place the cryopreservation bag in a programmable temperature controller, equilibrate at 4°C, cool to -80°C at a rate of 0.5-5°C / min, equilibrate, and then transfer to liquid nitrogen for freezing; (4) Rewarm the tube until the ice crystals melt, then remove the tube immediately and rinse the cryoprotectant with saline.
7. The method for freezing skin according to claim 6, characterized in that: The method of rewarming in step (4) is to immerse the cryobag in a 37°C water bath and shake it continuously.
